Drug Approval | August 27, 2021
Indoco’s AnaCipher receives UK-MHRA accreditation
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
It is the first branded generic alternative to Fostair 100/6 pMDI
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
Subscribe To Our Newsletter & Stay Updated
